Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is a publicly traded Healthcare sector company. As of May 20, 2026, PHAT trades at $11.51 with a market cap of $908.42M and a P/E ratio of -3.77. PHAT moved +0.35% today. Year to date, PHAT is -27.43%; over the trailing twelve months it is +159.68%. Its 52-week range spans $2.21 to $19.50. Analyst consensus is strong buy with an average price target of $24.25. Rallies surfaces PHAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phathom Presents 31 Vonoprazan Abstracts, Phase 3 Analysis Earns Poster Distinction: Phathom Pharmaceuticals showcased 31 vonoprazan abstracts at Digestive Disease Week 2026, including 28 independent studies on GERD, H. pylori eradication, long-term safety and post-ESD care plus three company-sponsored posters. Its Phase 3 pHalcon-NERD-301 analysis on heartburn and regurgitation earned Poster of Distinction recognition.
| Metric | Value |
|---|---|
| Price | $11.51 |
| Market Cap | $908.42M |
| P/E Ratio | -3.77 |
| EPS | $-3.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.50 |
| 52-Week Low | $2.21 |
| Volume | 186.89K |
| Avg Volume | 0 |
| Revenue (TTM) | $175.11M |
| Net Income | $-221.25M |
| Gross Margin | 87.09% |
6 analysts cover PHAT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.25.